Clinical trial · Observational
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
NCT02410603CI-TRIAL-00052816completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Cancer of Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Cancer of the Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Carcinoma, Non-small-cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasms, Lung | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasms, Pulmonary | Neoplasm | ONTOLOGY_EXACT | 0.85 |
| Pulmonary Cancer | — | UNRESOLVED | — |
| Pulmonary Neoplasms | — | UNRESOLVED | — |
| Squamous Cell Carcinoma | Squamous Cell Carcinoma |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary end point is the number and type of mutations detectable in the circulating tumor DNA blood samples.
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced (non-resectable) malignancy in the thorax * Age \>18 years old * Willing and able to provide consent * No prior history of neoadjuvant therapy Exclusion Criteria: * Age \<18 years old * Unable to provide consent * Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential iatrogenic anemia)
References
Publications (0)
Data not yet available
No reference posted for this study.